Evidence map›Paper›PMID 37179768›Full record

ArticleToxicology reports2023

Comparison of

Yuka Yoshino, Yuta Fujii, Kazuhiro Chihara, Aya Nakae, Jun-Ichiro Enmi, Yoshichika Yoshioka, Izuru Miyawaki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yuka YoshinoPreclinical Research Unit, Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Yuta FujiiPreclinical Research Unit, Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Kazuhiro ChiharaPreclinical Research Unit, Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
Aya NakaeGraduate School of Frontier Biosciences, Osaka University, 1-3 Yamadaoka, Suita city, Osaka 565-0871, Japan.
Jun-Ichiro EnmiGraduate School of Frontier Biosciences, Osaka University, 1-3 Yamadaoka, Suita city, Osaka 565-0871, Japan.
Yoshichika YoshiokaGraduate School of Frontier Biosciences, Osaka University, 1-3 Yamadaoka, Suita city, Osaka 565-0871, Japan.
Izuru MiyawakiPreclinical Research Unit, Sumitomo Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
National Institute of Information and Communications Technology · JPOsaka University · JPSumitomo Dainippon Pharma (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No method of monitoring drug-induced hepatic steatosis has been established, which is a concern in drug development. Hepatic steatosis is divided into diffuse and non-diffuse forms according to the pattern of fat deposition. Diffuse hepatic steatosis was reported as evaluable by

Indexed as

1H-magnetic resonance spectroscopyBlood biochemistryMagnetic resonance imagingMethionine choline deficient dietMonitorNon-diffuse hepatic steatosis

Identifiers

PMID37179768
PMCPMC10172911
OpenAlexW4365815728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.